Skip to main content
. 2021 Feb 26;6(6):1661–1668. doi: 10.1016/j.ekir.2021.02.018

Table 2.

Details of supportive therapy

ACEi/ARB (%) 81 (84.4) / 15 (15.6)
Dose of ACEi/ARB achieved (% of maximum labeled dose):
 100% 59 (61.5)
 75% 10 (10.4)
 50% 21 (21.9)
 < 50% 6 (6.3)
Requirement for additional antihypertensives (%) 54 (56.3)
Treatment for dyslipidemia (%) 26 (27.1)
Treatment for hyperuricemia (%) 44 (45.8)

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.